Michael Andrew Chambers Buys 57,100 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock
Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT Get Rating) Director Michael Andrew Chambers bought 57,100 shares of the stock in a transaction dated Wednesday, September 14th. The stock was bought at an average price of $108.28 per share, with a total value of $4,999,287.60.Shares of NASDAQ SRPT opened at $111.99 on Friday. American Century Companies Inc. bought a new stake in shares of Sarepta Therapeutics in the 1st quarter worth approximately $63,986,000. Wellington Management Group LLP lifted its holdings in shares of Sarepta Therapeutics by 33.6% in the 1st quarter. Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT) Stock Market: 3 Islands Of Strength In A Sea Of Red No One Told These 3 Stocks Its a Down Week Is There a Cure for What is Ailing Teladoc Stock?Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts ratings for Sarepta Therapeutics and related companies with MarketBeat.coms FREE daily email newsletter.
Classifications
AskAI Classifications
LabelsLinked Companies
